Trial Profile

A Phase Ib Study of Neoadjuvant Tislelizumab With Stereotactic Body Radiotherapy in Patients With Resectable Hepatocellular Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary)
Indications Liver cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Notable-HCC

Most Recent Events

02 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
24 Oct 2023 Interim results (as of 10th May 2023, n=11) presented at the 48th European Society for Medical Oncology Congress.
12 Aug 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com